What are the key terms of Michael Nofi’s 48,750-share stock option at Edgewise Therapeutics (EWTX)?

The stock option covers 48,750 shares of common stock with a stated exercise price of $0.0000 per share and expires on August 12, 2036. Vesting occurs as to 1/48 of the shares each month beginning September 12, 2026, subject to continued service.

Edgewise Therapeutics grants CFO RSUs and options

Q: What equity awards did Edgewise Therapeutics (EWTX) grant to its CFO Michael Nofi?

Edgewise Therapeutics granted CFO Michael Nofi 24,375 RSUs and a stock option for 48,750 shares of common stock. The RSUs and options vest over time, aligning his compensation with the company’s long-term performance and his continued service.

Q: How do the 24,375 RSUs granted to the EWTX CFO vest?

The 24,375 Restricted Stock Units vest in four equal annual installments starting on August 12, 2027. Each vested RSU entitles Michael Nofi to receive one share of Edgewise Therapeutics common stock, provided he continues in service through each vesting date.

Q: When does the monthly vesting of the EWTX CFO’s stock option begin and under what condition?

Monthly vesting of Michael Nofi’s stock option begins on September 12, 2026, with 1/48 of the shares vesting each month. Vesting is conditioned on him continuing as a service provider to Edgewise Therapeutics through each vesting date.

Q: Do the RSUs granted to the Edgewise Therapeutics (EWTX) CFO require additional cash payment?

The 24,375 RSUs were granted for no additional cash consideration. Each RSU represents a contingent right to receive one share of common stock upon vesting, which occurs in four equal annual installments beginning August 12, 2027, assuming continued service.

Q: What is the expiration date of the EWTX CFO’s new stock option grant?

Michael Nofi’s stock option grant for 48,750 shares of Edgewise Therapeutics common stock expires on August 12, 2036. Any unvested or unexercised portion after that date will lapse, consistent with the option’s stated expiration term.

Edgewise Therapeutics, Inc. granted its Chief Financial Officer, Michael Nofi, new equity awards.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. granted its Chief Financial Officer, Michael Nofi, new equity awards. 24,375 Restricted Stock Units were awarded for no additional cash consideration, each RSU representing one share of common stock, vesting in four equal annual installments starting August 12, 2027. In addition, a stock option for 48,750 shares of common stock with a stated exercise price of $0.0000 per share was granted, expiring August 12, 2036 and vesting as to 1/48 of the shares each month beginning September 12, 2026, subject to continued service.

Insider Trade Summary

Grant/Award: 73,125 shares

Grant/Award 2 txns

Insider Nofi Michael

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units ^F1	24,375	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy) ^F2	48,750	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 24,375 contracts (Direct); Stock Option (Right to Buy) — 48,750 contracts (Direct)

Footnotes (2)

F1. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.
F2. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Key Figures

RSUs granted: 24,375 shares Options granted: 48,750 shares RSU vesting start: August 12, 2027 +3 more

6 metrics

RSUs granted 24,375 shares Restricted Stock Units granted to CFO on August 12, 2026

Options granted 48,750 shares Stock Option (Right to Buy) granted to CFO on August 12, 2026

RSU vesting start August 12, 2027 RSUs vest in four equal annual installments beginning on this date

Option vesting start September 12, 2026 1/48 of option shares vest each month beginning on this date

Option expiration August 12, 2036 Expiration date for both RSU-related derivative entry and stock option

Option exercise price $0.0000 per share Stated conversion or exercise price for the 48,750-share stock option

Key Terms

Restricted Stock Units, contingent right, Stock Option (Right to Buy), service provider

4 terms

Restricted Stock Units financial

"Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"each of which represent a contingent right to receive one share of Edgewise"

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

service provider financial

"subject to the Reporting Person continuing as a service provider through each vest date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Edgewise Therapeutics (EWTX) grant to its CFO Michael Nofi?

Edgewise Therapeutics granted CFO Michael Nofi 24,375 RSUs and a stock option for 48,750 shares of common stock. The RSUs and options vest over time, aligning his compensation with the company’s long-term performance and his continued service.

How do the 24,375 RSUs granted to the EWTX CFO vest?

The 24,375 Restricted Stock Units vest in four equal annual installments starting on August 12, 2027. Each vested RSU entitles Michael Nofi to receive one share of Edgewise Therapeutics common stock, provided he continues in service through each vesting date.

When does the monthly vesting of the EWTX CFO’s stock option begin and under what condition?

Monthly vesting of Michael Nofi’s stock option begins on September 12, 2026, with 1/48 of the shares vesting each month. Vesting is conditioned on him continuing as a service provider to Edgewise Therapeutics through each vesting date.

Do the RSUs granted to the Edgewise Therapeutics (EWTX) CFO require additional cash payment?

The 24,375 RSUs were granted for no additional cash consideration. Each RSU represents a contingent right to receive one share of common stock upon vesting, which occurs in four equal annual installments beginning August 12, 2027, assuming continued service.

What is the expiration date of the EWTX CFO’s new stock option grant?

Michael Nofi’s stock option grant for 48,750 shares of Edgewise Therapeutics common stock expires on August 12, 2036. Any unvested or unexercised portion after that date will lapse, consistent with the option’s stated expiration term.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/14/2026 - 04:55 PM Accepted by SEC EDGAR 08/14/2026 - 04:54 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nofi Michael

(Last)

(First)

(Middle)

1715 38TH STREET

(Street)

BOULDER

COLORADO

80301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	$0.00	08/12/2026		A		24,375		⁽¹⁾	08/12/2036	Common Stock	24,375	$0.00	24,375	D
Stock Option (Right to Buy)	$0.00	08/12/2026		A		48,750		⁽²⁾	08/12/2036	Common Stock	48,750	$0.00	48,750	D

Explanation of Responses:

1. Restricted Stock Units ("RSUs") granted to the reporting person for no additional cash consideration, each of which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in four equal annual installments beginning on August 12, 2027.

2. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	/s/ John R. Moore, Attorney-in-Fact for Michael Nofi	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR